Table 2.
The IC50 values of compounds 1, 4, 8, 17, 22, and 28 harboring an anti-HIV-1 activity.
| Compounds | IC50 (µM) | |
|---|---|---|
| HIV-1 Infection (µM) | Cytotoxicity | |
| CE a | 9.98 ± 3.88 (µg/mL) | >1000 (μg/mL) |
| Cassiabrevone (1) | 11.89 ± 2.14 | >333 |
| Guibourtinidol-(4α→8)-epiafzelechin (4) | 15.39 ± 9.09 | >333 |
| Taxifolin (8) | 49.04 ± 5.02 | >333 |
| Oleanolic acid (17) | 7.95 ± 2.57 | >333 |
| Piceatannol (22) | 3.58 ± 0.27 | >333 |
| Palmitic acid (28) | 15.97 ± 3.04 | >333 |
| Enfuvirtide (T20) b | 0.0096 ± 0.001 | >1 |
| Plerixafor (AMD3100) b | 0.075 ± 0.009 | >1 |
a CE: crude extract of Cassia abbreviate. b Enfuvirtide and Plerixafor: positive controls. Each experiment was conducted three times and data were expressed as means ± SD.